Trial Profile
Phase II study of atezolizumab for advanced non-small-cell lung cancer patients not indicative of cytotoxic chemotherapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 May 2022
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 18 May 2022 Status changed from recruiting to discontinued.
- 04 Jul 2018 New trial record